Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ole Kirk

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
Journal of the International AIDS Society|November 14, 2014
Treatment and care of TB across EuropeOle Kirk
Current Opinion in HIV and AIDS|December 29, 2025
Mycobacterium tuberculosis in HIV co-infection: a growing concern in Europe?Christian Kraef, Ole Kirk
Current Opinion in Infectious Diseases|April 20, 2004
Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicinesOle Kirk, Jens D Lundgren
Angewandte Chemie (International Ed. in English)|May 2, 2018
Metal-Free Haloperoxidases: Fact or Artifact?Ole Kirk, Lars Sparre Conrad
Current Opinion in Biotechnology|September 27, 2002
Industrial enzyme applicationsOle Kirk, Torben Vedel Borchert, Claus Crone Fuglsang
Ugeskrift for Laeger|March 7, 2009
[Major breakthroughs in the medical treatment]Ole Kirk, Jan Gerstoft, Jens D Lundgren, et al.
Ugeskrift for Laeger|March 22, 2022
[New and rediscovered treatments for tuberculosis]Christian Kraef, Troels Lillebæk, Åse Bengård Andersen, et al.
Scandinavian Journal of Infectious Diseases|March 5, 2002
The naive CD4+ count in HIV-1-infected patients at time of initiation of highly active antiretroviral therapy is strongly associated with the level of immunological recoveryChristian G Michael, Ole Kirk, Lars Mathiesen, et al.
Swiss Medical Weekly|August 22, 2016
Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do betterKatharine Ea Darling, Anna Hachfeld, Matthias Cavassini, et al.
Ugeskrift for Laeger|May 16, 2017
[The current global tuberculosis state]Christian Wejse, Troels Lillebæk, Ole Kirk, et al.
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
Journal of the International AIDS Society|November 14, 2014
Treatment and care of TB across EuropeOle Kirk
Current Opinion in HIV and AIDS|December 29, 2025
Mycobacterium tuberculosis in HIV co-infection: a growing concern in Europe?Christian Kraef, Ole Kirk
Current Opinion in Infectious Diseases|April 20, 2004
Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicinesOle Kirk, Jens D Lundgren
Angewandte Chemie (International Ed. in English)|May 2, 2018
Metal-Free Haloperoxidases: Fact or Artifact?Ole Kirk, Lars Sparre Conrad
Current Opinion in Biotechnology|September 27, 2002
Industrial enzyme applicationsOle Kirk, Torben Vedel Borchert, Claus Crone Fuglsang
Ugeskrift for Laeger|March 7, 2009
[Major breakthroughs in the medical treatment]Ole Kirk, Jan Gerstoft, Jens D Lundgren, et al.
Ugeskrift for Laeger|March 22, 2022
[New and rediscovered treatments for tuberculosis]Christian Kraef, Troels Lillebæk, Åse Bengård Andersen, et al.
Scandinavian Journal of Infectious Diseases|March 5, 2002
The naive CD4+ count in HIV-1-infected patients at time of initiation of highly active antiretroviral therapy is strongly associated with the level of immunological recoveryChristian G Michael, Ole Kirk, Lars Mathiesen, et al.
Swiss Medical Weekly|August 22, 2016
Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do betterKatharine Ea Darling, Anna Hachfeld, Matthias Cavassini, et al.
Ugeskrift for Laeger|May 16, 2017
[The current global tuberculosis state]Christian Wejse, Troels Lillebæk, Ole Kirk, et al.
Pageof 18